Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Positive results from Factor IX-CTP comparative study in hemophilic mice

PROLOR Biotech, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX in Factor IX-depleted hemophilic mice.

3 Feb 2011

Widespread screening or ultrasound for blocked neck arteries not necessary to determine stroke risk

Widespread screening or routine ultrasound for blocked neck arteries to determine stroke risk isn't necessary, according to new guidelines from the American Heart Association/American Stroke Association, American College of Cardiology and other groups.

1 Feb 2011

Single DNA variation linked to decreased risk of coronary disease in African-Americans

A team of scientists at Johns Hopkins and elsewhere has discovered that a single alteration in the genetic code of about a fourth of African-Americans helps protect them from coronary artery disease, the leading cause of death in Americans of all races.

28 Jan 2011

Study aims to determine risk of dementia, cognitive decline in middle-aged people

University of North Carolina at Chapel Hill researchers are co-leading a national study to examine whether middle-aged people's physical health influences their risk of dementia later in life.

28 Jan 2011

Cardiac stem cell therapy can rebuild damaged heart in children

Visionaries in the field of cardiac therapeutics have long looked to the future when a damaged heart could be rebuilt or repaired by using one's own heart cells. A study published in the February issue of Circulation, a scientific journal of the American Heart Association, shows that heart stem cells from children with congenital heart disease were able to rebuild the damaged heart in the laboratory.

27 Jan 2011

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Researchers in China have demonstrated interferon-alpha (IFN-α) is associated with increased risk of atherosclerosis in patients with systemic lupus erythematosus (SLE). For the first time, IFN-α priming was shown to promote lipid uptake and foam cell formation—a crucial step in plaque build-up. This activation of the IFN signaling pathway may be linked to the premature atherosclerosis risk in SLE.

27 Jan 2011

Scientists to develop enzyme that protects against nerve agents

Protection against nerve gas attack is a significant component of the defense system of many countries around the world. Nerve gases are used by armies and terrorist organizations, and constitute a threat to both the military and civilian populations, but existing drug solutions against them have limited efficiency.

25 Jan 2011

Human model of rare genetic disease reveals new clues to aging process

Scientists from A*STAR's Institute of Medical Biology (IMB) in Singapore and the University of Hong Kong's Department of Medicine have produced the world's first human cell model of progeria, a disease resulting in severe premature ageing in one in four to eight million children worldwide. This model has allowed them to make new discoveries concerning the mechanism by which progeria works.

25 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

Functional tests are necessary to understand human disease despite genetic sequencing

Despite what you might have heard, genetic sequencing alone is not enough to understand human disease. Researchers at Duke University Medical Center have shown that functional tests are absolutely necessary to understand the biological relevance of the results of sequencing studies as they relate to disease, using a suite of diseases known as the ciliopathies which can cause patients to have many different traits.

24 Jan 2011

Stusy: HEPA filters may help reduce pollution-related cardiovascular health risks

Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adultsliving in a small community in British Columbia where wood burning stoves are the main sources of pollution.

24 Jan 2011

Routine mammograms can show arterial calcium deposits in women with ESRD, CKD

Routine mammograms performed for breast cancer screening could serve another purpose as well: detecting calcifications in the blood vessels of patients with advanced kidney disease, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology.

21 Jan 2011

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

Results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

21 Jan 2011

BUSM receives NIH grant to explore how chronic inflammation can lead to systemic diseases

A team of researchers at Boston University School of Medicine have been awarded a five-year, $7.7 million grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases to explore how chronic inflammation can lead to systemic diseases.

20 Jan 2011

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Merck reported today that investigators in the TRA-2P study of vorapaxar have been provided with additional information about the recommendations of the Data and Safety Monitoring Board (DSMB) regarding the TRA-2P study. The additional information was sent yesterday in a communication to investigators from the Operations Committee of the TRA-2P study of vorapaxar. Vorapaxar is one of Merck's investigational cardiovascular medicines.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Merck announces changes in vorapaxar clinical studies

Merck today provided the following statement on the changes to the clinical studies for vorapaxar, one of the Company's investigational cardiovascular medicines, following an announcement from the two academic centers leading the studies of vorapaxar.

14 Jan 2011

Atherosclerosis News and Research

Further Reading

Positive results from Factor IX-CTP comparative study in hemophilic mice

Widespread screening or ultrasound for blocked neck arteries not necessary to determine stroke risk

Single DNA variation linked to decreased risk of coronary disease in African-Americans

Study aims to determine risk of dementia, cognitive decline in middle-aged people

Cardiac stem cell therapy can rebuild damaged heart in children

Interferon-alpha associated with increased risk of atherosclerosis in patients with SLE

Scientists to develop enzyme that protects against nerve agents

Human model of rare genetic disease reveals new clues to aging process

KineMed's fibrosis research program featured in Nature Medicine

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Functional tests are necessary to understand human disease despite genetic sequencing

Stusy: HEPA filters may help reduce pollution-related cardiovascular health risks

Routine mammograms can show arterial calcium deposits in women with ESRD, CKD

PROSPECT trial results shed new light on plaque types that cause unexpected heart attacks

BUSM receives NIH grant to explore how chronic inflammation can lead to systemic diseases

Merck provides additional information about DSMB recommendations for vorapaxar TRA-2P study

Endothelial cells may play a role in controlling cancer behavior: New study

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Merck announces changes in vorapaxar clinical studies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News